The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB.
about
Multicomponent meningococcal B vaccination (4CMenB) of adolescents and college students in the United StatesDiversity of Greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccineMeningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents.Molecular and serological diversity of Neisseria meningitidis carrier strains isolated from Italian students aged 14 to 22 years.Effect of human serum on de-N-acetyl sialic acid epitope expression and antibody activity against N. meningitidis group BLOS oligosaccharide modification enhances dendritic cell responses to meningococcal native outer membrane vesicles expressing a non-toxic lipid AConstruction of Opa-positive and Opa-negative strains of Neisseria meningitidis to evaluate a novel meningococcal vaccine.Disease-associated Neisseria meningitidis isolates inhibit wound repair in respiratory epithelial cells in a type IV pilus-independent mannerImproved production process for native outer membrane vesicle vaccine against Neisseria meningitidis.Molecular characterization of invasive Neisseria meningitidis strains isolated in Chile during 2010-2011The Neisseria meningitidis macrophage infectivity potentiator protein induces cross-strain serum bactericidal activity and is a potential serogroup B vaccine candidate.Vaccine preventability of meningococcal clone, Greater Aachen Region, Germany.Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England.Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines.A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial.Ion torrent personal genome machine sequencing for genomic typing of Neisseria meningitidis for rapid determination of multiple layers of typing informationTemporal Changes in BEXSERO® Antigen Sequence Type Associated with Genetic Lineages of Neisseria meningitidis over a 15-Year Period in Western Australia.Comparison of phenotypically indistinguishable but geographically distinct Neisseria meningitidis Group B isolates in a serum bactericidal antibody assayInterlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccinesBactericidal antibody responses induced by meningococcal recombinant chimeric factor H-binding protein vaccines.Phase variation of PorA, a major outer membrane protein, mediates escape of bactericidal antibodies by Neisseria meningitidisVaccinology in the genome era.Challenges and progress in the development of a serogroup B meningococcal vaccine.Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future.Neisseria meningitidis native outer membrane vesicles containing different lipopolysaccharide glycoforms as adjuvants for meningococcal and nonmeningococcal antigens.Serum Bactericidal Antibody Responses of Adults Immunized with the MenB-4C Vaccine against Genetically Diverse Serogroup B Meningococci.Meningococcal serogroup B vaccines: Estimating breadth of coverage.Opa proteins and CEACAMs: pathways of immune engagement for pathogenic Neisseria.A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease.New frontiers in meningococcal vaccines.A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?Neisseria meningitidis B vaccines: recent advances and possible immunization policies.The Long Road to an Effective Vaccine for Meningococcus Group B (MenB).Frequent capsule switching in 'ultra-virulent' meningococci - Are we ready for a serogroup B ST-11 complex outbreak?The next chapter for group B meningococcal vaccines.Novel approaches to Neisseria meningitidis vaccine design.Discordant Effects of Licensed Meningococcal Serogroup B Vaccination on Invasive Disease and Nasal Colonization in a Humanized Mouse Model.Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine.Understanding the immune responses to the meningococcal strain-specific vaccine MeNZB measured in studies of infants.Meningococcal omp85 in detergent-extracted outer membrane vesicle vaccines induces high levels of non-functional antibodies in mice.
P2860
Q30235072-BAF3A253-A7CA-4A0B-9884-87C8019C65E6Q33600936-D30BC6CE-EFE1-4D7F-AF22-96905215C8E8Q33609246-BB6CCE92-549E-4C4D-AC14-14CD23852DF9Q33703560-204C4744-5EB8-4C8A-963F-874257C71623Q34076321-67DA8A75-9879-42E4-9E6F-DCA7BA09762AQ34376049-14CAAD2C-795B-4F5E-8760-568AE61EFF42Q34516060-DB8B49EB-F03C-4DA6-8116-41632B35464EQ34595752-BDA0A7D4-804C-4F1F-AB24-B429668B8E89Q34761285-FC88E03A-A036-4890-9D9F-55CAED077A7FQ34776133-F443CF87-6735-46D6-9D3D-B3058C1C3180Q35191903-082752D1-7359-4DA5-B529-E2D507540A3DQ35877401-0A1D99FB-0F45-452F-ABB5-27F5989F9308Q35946870-59120F66-D842-4A8F-B600-60046C32226DQ35946901-889890CE-95D1-4998-836D-F32267830846Q35949585-73337059-082B-4DD9-BC9C-6CA97948856FQ36022991-1AD0E5C2-B157-450F-906B-2408B5DA3C30Q36064003-3A738560-09CF-4FA9-BCD2-70E7910941E1Q36313615-8F0A29AB-21C8-43E9-BE72-6DD27B09353EQ36362282-1FE95915-3BA9-44DD-B52D-2BAC950F7A1FQ36710765-A17FD490-F63E-4702-B6B9-8D57F22826A5Q36804674-6054D086-879D-440E-8650-68B4F43DAD65Q37328536-71FF6D3E-3B14-404C-A9D2-152194111F3EQ37503243-95F29584-2D4D-40D8-86F5-2B921B720D30Q37514748-3DBACD95-E78D-4E73-90F0-2000F798B4DFQ37545048-EB8244DD-FA1D-412E-9129-7EB47D3AEFCDQ37563627-53E7A386-40A4-4482-83CD-FDE72843BE5AQ37669413-570D7BFE-3C69-40F1-AE38-5266E4FBD6BCQ37825922-A4C06D7D-A434-4E07-ACDE-ED523C40FF6FQ37878478-3CA5F032-1D89-4A7F-AD5C-A0135441CC59Q37878480-CDE3550D-76BB-4B83-8217-E74F549E4047Q38132262-ACF3B0D0-60FB-47A4-B092-7FFBAE71C790Q38183156-D5AA662E-68C7-427E-9AAA-8604028B0876Q38335257-7DA9E534-1AC6-44D1-B68B-E9A9C8F90F5CQ38674983-82300E3D-B588-4CE4-BC47-36096A701D17Q38677309-4CA0A8A1-AFCF-4BDA-A3E3-25172EE0976EQ39215403-74F20A4F-7732-441D-9A52-42B938AC556BQ40268050-395B2424-BDA0-4F79-9881-8DA6D6FD8963Q41012990-F2F8353B-B0FB-466C-8DDC-7EE190E736E2Q41479856-B2EBD8F9-2655-4B22-9D13-4F07C7403B4DQ42269802-7BFD9051-82F0-467B-BFDA-051CFF49AE68
P2860
The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB.
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
The VR2 epitope on the PorA P1 ...... B meningococcal vaccine MeNZB.
@ast
The VR2 epitope on the PorA P1 ...... B meningococcal vaccine MeNZB.
@en
The VR2 epitope on the PorA P1 ...... B meningococcal vaccine MeNZB.
@nl
type
label
The VR2 epitope on the PorA P1 ...... B meningococcal vaccine MeNZB.
@ast
The VR2 epitope on the PorA P1 ...... B meningococcal vaccine MeNZB.
@en
The VR2 epitope on the PorA P1 ...... B meningococcal vaccine MeNZB.
@nl
prefLabel
The VR2 epitope on the PorA P1 ...... B meningococcal vaccine MeNZB.
@ast
The VR2 epitope on the PorA P1 ...... B meningococcal vaccine MeNZB.
@en
The VR2 epitope on the PorA P1 ...... B meningococcal vaccine MeNZB.
@nl
P2093
P2860
P1476
The VR2 epitope on the PorA P1 ...... B meningococcal vaccine MeNZB.
@en
P2093
P2860
P304
P356
10.1128/CVI.13.4.486-491.2006
P577
2006-04-01T00:00:00Z